Kingdon Capital Management’s Amphastar Pharmaceuticals AMPH Stock Holding History

Kingdon Capital Management’s Portfolio AMPH Stock Details AMPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-206,539	Closed	-$3.63M	–	128
2015 Q2	$3.63M	Sell	206,539 -118,800	-37%	-$1.85M	0.14%	107
2015 Q1	$4.87M	Sell	325,339 -145,000	-31%	-$1.94M	0.21%	114
2014 Q4	$5.46M	Buy	470,339 +195,339	+71%	+$2.13M	0.24%	99
2014 Q3	$3.2M	Buy	+275,000	New	+$2.86M	0.14%	130

Other funds holding AMPH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

TFS Capital West Chester, Pennsylvania $255M AUM 32.31% 1-Year Est. Return

Kingdon Capital Management's AMPH Position: Q3 2015 in Review

Kingdon Capital Management sold out of Amphastar Pharmaceuticals (AMPH) in Q3 2015, closing a stake of 206,539 shares — an estimated $3.63M sold.

Kingdon Capital Management first reported a position in AMPH in Q3 2014 and held it in 4 quarters. The position peaked at $5.46M in Q4 2014. 92 funds tracked by Wall St. Rank hold AMPH as of Q3 2015.

Kingdon Capital Management reported no remaining Amphastar Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
Kingdon Capital Management sold 206,539 Amphastar Pharmaceuticals shares in Q3 2015, an estimated $3.63M.
Kingdon Capital Management first reported a position in Amphastar Pharmaceuticals in Q3 2014 and held it in 4 quarters.
Kingdon Capital Management's Amphastar Pharmaceuticals position peaked at $5.46M in Q4 2014.
92 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q3 2015.

Based on Kingdon Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.